Star Imaging IPO: GMP, Key Details & Expert Review (August 2025)
Star Imaging IPO:
Grey Market Premium (GMP) & Latest Updates
As of August 9, 2025, the Grey Market Premium (GMP) for Star Imaging IPO stands at ₹0 per share, implying that the estimated listing price is expected to be close to the IPO upper price band of ₹142. This suggests minimal to no immediate listing gains based on current market sentiment.
Star Imaging IPO GMP Trend Summary
Date IPO Price Band GMP Estimated Listing Price Estimated Listing Gain
08 Aug 25 ₹135 - ₹142 ₹0 ₹142 0.00%
07 Aug 25 ₹135 - ₹142 ₹0 ₹142 0.00%
06 Aug 25 ₹135 - ₹142 ₹0 ₹142 0.00%
GMP values may vary as the subscription period progresses.
Key IPO Details
IPO Open Date: August 8, 2025
IPO Close Date: August 12, 2025
Price Band: ₹135 to ₹142 per share
Lot Size: 1,000 shares (Minimum application: 2 lots = 2,000 shares; approx. ₹2,70,000 to ₹2,84,000)
Issue Size: Approx ₹69.47 crore (Fresh issue ₹55.66 crore + Offer for sale ₹13.80 crore)
Listing Date: August 18, 2025 on BSE SME
Face Value: ₹10 per share
Registrar: Kfin Technologies Limited
Business Overview
Star Imaging and Path Lab Limited, founded in 2004, is a prominent diagnostic services company providing extensive imaging and pathology services such as X-rays, ultrasounds, CT scans, MRIs, blood and urine tests, and specialized diagnostics. The company serves individuals and healthcare institutions across multiple regions. It started in 1978 as a proprietorship offering basic diagnostic services and has grown substantially by adopting advanced technology and skilled professionals.
IPO Objectives
The proceeds from the IPO will be used primarily for:
Prepayment or repayment of borrowings
Funding capital expenditure including purchasing refurbished medical equipment
General corporate purposes
Meeting working capital requirements
Subscription Status & Market Sentiment
The IPO opened on August 8, 2025, and the initial subscription shows cautious investor participation with low grey market premium currently reflecting neutral market expectations. Retail investors need to bid for a minimum of 2 lots (2,000 shares) indicating a sizeable investment. Institutional investor subscription has been limited as of the early days of IPO subscription.
Analyst Review: Should You Invest?
Pros: Established presence in diagnostic healthcare, steady financial growth, use of advanced technology, and wide service network.
Cons: High minimum investment for retail investors, SME segment risks, and current zero GMP reflecting modest short-term listing gains.
Verdict: Suitable for investors with a medium to long-term perspective seeking exposure in healthcare diagnostics. Immediate listing gains may be limited, so careful evaluation of company fundamentals and sector outlook is advised before investing.
